Cochrane · systematic review · CD008078
Alemtuzumab for patients with chronic lymphocytic leukaemia
Skoetz, N, Bauer, K, Elter, T, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
9
No studies
2
Included studies
NR
No studies 2 · 18.2%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 36.4%Moderate 4 · 36.4%High 1 · 9.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐leukaemic therapy plus alemtuzumab versus anti‐leukaemic therapy alone (anti‐leukaemic therapy identical in both groups; unconfounded) for chronic lymphocytic leukaemia
Population: patients with chronic lymphocytic leukaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (median 2 years) Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical | HR 0.65 [0.45, 0.94] | 1 study · 335 participants | Moderate |
Progression free survival (median 2 years) Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical | HR 0.61 [0.47, 0.81] | 2 studies · 356 participants | Low Downgraded: inconsistency |
Treatment related mortality Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical | RR 0.57 [0.17, 1.9] | 2 studies · 356 participants | Moderate Downgraded: inconsistency |
Cytomegalovirus reactivation Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical | RR 10.52 [1.42, 77.68] | 2 studies · 350 participants | High |
Complete response rate Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical | RR 2.61 [1.26, 5.42] | 2 studies · 356 participants | Low Downgraded: inconsistency |
Infections (all grades) Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical | RR 1.32 [1.01, 1.74] | 2 studies · 356 participants | Low Downgraded: inconsistency |
Serious adverse events Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical | RR 1.34 [0.95, 1.89] | 2 studies · 350 participants | Moderate Downgraded: inconsistency |
Anti‐leukaemic therapy with alemtuzumab versus anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical in both groups, confounded) for chronic lymphocytic leukaemia
Population: patients with chronic lymphocytic leukaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival not reported Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical | no estimate extracted | NR | No studies |
Progression free survival not reported Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical | no estimate extracted | NR | No studies |
Treament related mortality Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical | RR 3.2 [0.66, 15.5] | 2 studies · 177 participants | Low |
Complete response rate Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical | RR 0.85 [0.67, 1.08] | 2 studies · 170 participants | Moderate |